New Patient-Oriented Tools for Assessing Atrophic Acne Scarring

Alison Layton, Brigitte Dréno, Andrew Y. Finlay, Diane Thiboutot, Sewon Kang, Vicente Torres Lozada, Valerie Bourdès, Vincenzo Bettoli, Laurent Petit, Jerry Tan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Scarring on visible areas such as the face is associated with negative psychological impact. Many patients with acne have clinically relevant scarring for which they seek treatment, implying that there is an impact on their lives. Currently there are no validated tools to assess the burden of atrophic acne scarring from the patient’s perspective or to assess treatment benefit. Methods: Two patient-reported outcome measures, the self-assessment of clinical acne-related scars (SCARS) and the facial acne scar quality of life (FASQoL) tools, both specific to facial atrophic acne scarring, were developed according to Food and Drug Administration guidance methodology. Patient interviews were conducted first to elicit patient-important concepts about scarring, then to validate patients’ understanding of wording in the tools. These tools focus on symptoms (SCARS) and psychological and social well-being (FASQoL) and were designed to be suitable for self-completion and to be rapidly completed (2–5 min) within a clinical research setting. Results: Concept elicitation interviews were conducted with 30 subjects and cognitive interviews with 20 subjects. With acne scarring, important concepts for patients included size, surface area affected, counts, and depth. The SCARS and FASQoL tools were shown to address relevant concepts that were easily understood by patients. Conclusion: Two patient-reported measures, SCARS and FASQoL, have been developed to help clinicians assess the severity and impact of acne scars. Responsivity of these instruments to treatment will require further evaluation. Funding: Galderma R&D, Sophia Antipolis, France.

Original languageEnglish (US)
Pages (from-to)219-233
Number of pages15
JournalDermatology and Therapy
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

Acne Vulgaris
Cicatrix
Quality of Life
Interviews
Psychology
United States Food and Drug Administration
France
Therapeutics

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Layton, A., Dréno, B., Finlay, A. Y., Thiboutot, D., Kang, S., Lozada, V. T., ... Tan, J. (2016). New Patient-Oriented Tools for Assessing Atrophic Acne Scarring. Dermatology and Therapy, 6(2), 219-233. https://doi.org/10.1007/s13555-016-0098-5
Layton, Alison ; Dréno, Brigitte ; Finlay, Andrew Y. ; Thiboutot, Diane ; Kang, Sewon ; Lozada, Vicente Torres ; Bourdès, Valerie ; Bettoli, Vincenzo ; Petit, Laurent ; Tan, Jerry. / New Patient-Oriented Tools for Assessing Atrophic Acne Scarring. In: Dermatology and Therapy. 2016 ; Vol. 6, No. 2. pp. 219-233.
@article{11a9eac8d7af471daf9115fbcdcd1070,
title = "New Patient-Oriented Tools for Assessing Atrophic Acne Scarring",
abstract = "Introduction: Scarring on visible areas such as the face is associated with negative psychological impact. Many patients with acne have clinically relevant scarring for which they seek treatment, implying that there is an impact on their lives. Currently there are no validated tools to assess the burden of atrophic acne scarring from the patient’s perspective or to assess treatment benefit. Methods: Two patient-reported outcome measures, the self-assessment of clinical acne-related scars (SCARS) and the facial acne scar quality of life (FASQoL) tools, both specific to facial atrophic acne scarring, were developed according to Food and Drug Administration guidance methodology. Patient interviews were conducted first to elicit patient-important concepts about scarring, then to validate patients’ understanding of wording in the tools. These tools focus on symptoms (SCARS) and psychological and social well-being (FASQoL) and were designed to be suitable for self-completion and to be rapidly completed (2–5 min) within a clinical research setting. Results: Concept elicitation interviews were conducted with 30 subjects and cognitive interviews with 20 subjects. With acne scarring, important concepts for patients included size, surface area affected, counts, and depth. The SCARS and FASQoL tools were shown to address relevant concepts that were easily understood by patients. Conclusion: Two patient-reported measures, SCARS and FASQoL, have been developed to help clinicians assess the severity and impact of acne scars. Responsivity of these instruments to treatment will require further evaluation. Funding: Galderma R&D, Sophia Antipolis, France.",
author = "Alison Layton and Brigitte Dr{\'e}no and Finlay, {Andrew Y.} and Diane Thiboutot and Sewon Kang and Lozada, {Vicente Torres} and Valerie Bourd{\`e}s and Vincenzo Bettoli and Laurent Petit and Jerry Tan",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s13555-016-0098-5",
language = "English (US)",
volume = "6",
pages = "219--233",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "2",

}

Layton, A, Dréno, B, Finlay, AY, Thiboutot, D, Kang, S, Lozada, VT, Bourdès, V, Bettoli, V, Petit, L & Tan, J 2016, 'New Patient-Oriented Tools for Assessing Atrophic Acne Scarring', Dermatology and Therapy, vol. 6, no. 2, pp. 219-233. https://doi.org/10.1007/s13555-016-0098-5

New Patient-Oriented Tools for Assessing Atrophic Acne Scarring. / Layton, Alison; Dréno, Brigitte; Finlay, Andrew Y.; Thiboutot, Diane; Kang, Sewon; Lozada, Vicente Torres; Bourdès, Valerie; Bettoli, Vincenzo; Petit, Laurent; Tan, Jerry.

In: Dermatology and Therapy, Vol. 6, No. 2, 01.06.2016, p. 219-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New Patient-Oriented Tools for Assessing Atrophic Acne Scarring

AU - Layton, Alison

AU - Dréno, Brigitte

AU - Finlay, Andrew Y.

AU - Thiboutot, Diane

AU - Kang, Sewon

AU - Lozada, Vicente Torres

AU - Bourdès, Valerie

AU - Bettoli, Vincenzo

AU - Petit, Laurent

AU - Tan, Jerry

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Introduction: Scarring on visible areas such as the face is associated with negative psychological impact. Many patients with acne have clinically relevant scarring for which they seek treatment, implying that there is an impact on their lives. Currently there are no validated tools to assess the burden of atrophic acne scarring from the patient’s perspective or to assess treatment benefit. Methods: Two patient-reported outcome measures, the self-assessment of clinical acne-related scars (SCARS) and the facial acne scar quality of life (FASQoL) tools, both specific to facial atrophic acne scarring, were developed according to Food and Drug Administration guidance methodology. Patient interviews were conducted first to elicit patient-important concepts about scarring, then to validate patients’ understanding of wording in the tools. These tools focus on symptoms (SCARS) and psychological and social well-being (FASQoL) and were designed to be suitable for self-completion and to be rapidly completed (2–5 min) within a clinical research setting. Results: Concept elicitation interviews were conducted with 30 subjects and cognitive interviews with 20 subjects. With acne scarring, important concepts for patients included size, surface area affected, counts, and depth. The SCARS and FASQoL tools were shown to address relevant concepts that were easily understood by patients. Conclusion: Two patient-reported measures, SCARS and FASQoL, have been developed to help clinicians assess the severity and impact of acne scars. Responsivity of these instruments to treatment will require further evaluation. Funding: Galderma R&D, Sophia Antipolis, France.

AB - Introduction: Scarring on visible areas such as the face is associated with negative psychological impact. Many patients with acne have clinically relevant scarring for which they seek treatment, implying that there is an impact on their lives. Currently there are no validated tools to assess the burden of atrophic acne scarring from the patient’s perspective or to assess treatment benefit. Methods: Two patient-reported outcome measures, the self-assessment of clinical acne-related scars (SCARS) and the facial acne scar quality of life (FASQoL) tools, both specific to facial atrophic acne scarring, were developed according to Food and Drug Administration guidance methodology. Patient interviews were conducted first to elicit patient-important concepts about scarring, then to validate patients’ understanding of wording in the tools. These tools focus on symptoms (SCARS) and psychological and social well-being (FASQoL) and were designed to be suitable for self-completion and to be rapidly completed (2–5 min) within a clinical research setting. Results: Concept elicitation interviews were conducted with 30 subjects and cognitive interviews with 20 subjects. With acne scarring, important concepts for patients included size, surface area affected, counts, and depth. The SCARS and FASQoL tools were shown to address relevant concepts that were easily understood by patients. Conclusion: Two patient-reported measures, SCARS and FASQoL, have been developed to help clinicians assess the severity and impact of acne scars. Responsivity of these instruments to treatment will require further evaluation. Funding: Galderma R&D, Sophia Antipolis, France.

UR - http://www.scopus.com/inward/record.url?scp=84975801226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975801226&partnerID=8YFLogxK

U2 - 10.1007/s13555-016-0098-5

DO - 10.1007/s13555-016-0098-5

M3 - Article

C2 - 26886873

AN - SCOPUS:84975801226

VL - 6

SP - 219

EP - 233

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 2

ER -